Incidence of serious adverse events in TOP*
Event, n (%) | n=6148 |
Patients with ≥1 SAE | 829 (13.5) |
SAEs by SOC and MedDRA preferred term reported in >5 patients* | |
Infections and infestations | 254 (4.1) |
PML, confirmed | 53 (0.9) |
Pneumonia | 23 (0.4) |
Urinary tract infection | 20 (0.3) |
Herpes zoster | 17 (0.3) |
Escherichia urinary tract infection | 12 (0.2) |
Pyelonephritis | 10 (0.2) |
Appendicitis | 8 (0.1) |
Diverticulitis | 6 (0.1) |
Gastroenteritis | 6 (0.1) |
Sepsis | 6 (0.1) |
Nervous system† | 142 (2.3) |
Epilepsy | 18 (0.3) |
MS | 15 (0.2) |
Syncope | 8 (0.1) |
Headache | 7 (0.1) |
Sciatica | 6 (0.1) |
Uhthoff’s phenomenon | 6 (0.1) |
Immune system disorders | 92 (1.5) |
Immune reconstitution inflammatory syndrome‡ | 54 (0.9) |
Hypersensitivity | 26 (0.4) |
Neoplasms benign, malignant and unspecified (including cysts and polyps) | 88 (1.4) |
Breast cancer | 12 (0.2) |
Uterine leiomyoma | 9 (0.1) |
Injury, poisoning and procedural complications | 75 (1.2) |
Fall | 19 (0.3) |
Psychiatric disorders | 69 (1.1) |
Depression | 18 (0.3) |
Suicide attempt | 11 (0.2) |
Completed suicide | 7 (0.1) |
Pregnancy, puerperium and perinatal conditions | 55 (0.9) |
Abortion spontaneous | 37 (0.6) |
Musculoskeletal and connective tissue disorders | 48 (0.8) |
Intervertebral disc protrusion | 12 (0.2) |
Back pain | 8 (0.1) |
Surgical and medical procedures | 37 (0.6) |
Caesarean section | 8 (0.1) |
General disorders and administration site conditions | 32 (0.5) |
Fever | 6 (0.1) |
Respiratory, thoracic and mediastinal disorders | 26 (0.4) |
Pulmonary embolism | 10 (0.2) |
Hepatobiliary disorders | 24 (0.4) |
Cholelithiasis | 7 (0.1) |
Vascular disorders | 19 (0.3) |
Deep vein thrombosis | 6 (0.1) |
*Each patient was counted only once within each preferred term.
†MS relapse was also reported as an SAE in 20 patients (0.3%).
‡One case of immune reconstitution inflammatory syndrome was not associated with PML.
MedDRA, Medical Dictionary for Regulatory Activities; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy; SAE, serious adverse event; SOC, system organ class; TOP, Tysabri Observational Programme.